Comparison 2. GPA ‐ anticytokine therapy vs control.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Mortality	3		Peto Odds Ratio (Peto, Fixed, 95% CI)	Subtotals only
2.1.1 Active drug vs placebo	2	285	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.45 [0.55, 10.97]
2.1.2 Infliximab vs rituximab	1	17	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.88 [0.05, 15.51]
2.2 Remission	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.2.1 Etanercept vs placebo, remission at any time during study	1	180	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.89, 1.07]
2.2.2 Infliximab vs rituximab	1	17	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.11, 1.81]
2.3 Durable remission	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.3.1 Etanercept vs placebo	1	174	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.77, 1.11]
2.3.2 Infliximab vs rituximab long term	1	17	Risk Ratio (M‐H, Random, 95% CI)	0.22 [0.03, 1.60]
2.4 Disease relapse	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.4.1 Any relapse ‐ belimumab vs placebo	1	105	Risk Ratio (M‐H, Random, 95% CI)	0.74 [0.27, 1.97]
2.4.2 Major relapse ‐ belimumab vs placebo	1	105	Risk Ratio (M‐H, Random, 95% CI)	2.94 [0.12, 70.67]
2.5 No disease flare	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.5.1 Etanercept vs placebo	1	180	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.76, 1.27]
2.6 Any AE	1	105	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.97, 1.29]
2.7 Any non serious AE	1	105	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.70, 1.28]
2.7.1 Belimumab vs placebo	1	105	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.70, 1.28]
2.8 Any severe or serious AE	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.8.1 Active drug vs placebo	2	285	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.80, 1.27]
2.8.2 Infliximab vs rituximab	1	17	Risk Ratio (M‐H, Random, 95% CI)	1.78 [0.20, 16.10]
2.9 Any solid malignancy	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.9.1 During trial and follow up	1	180	Risk Ratio (M‐H, Random, 95% CI)	2.86 [1.08, 7.62]
2.9.2 During trial	1	180	Risk Ratio (M‐H, Random, 95% CI)	13.29 [0.76, 232.45]
2.9.3 During follow up	1	153	Risk Ratio (M‐H, Random, 95% CI)	1.58 [0.54, 4.61]
2.10 Any withdrawals due to AE	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.10.1 Active drug vs placebo	2	285	Risk Ratio (M‐H, Random, 95% CI)	2.66 [1.07, 6.59]
2.10.2 Infliximab vs rituximab	1	17	Risk Ratio (M‐H, Random, 95% CI)	2.70 [0.13, 58.24]
2.11 Treatment response	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.11.1 Sustained low level of disease activity (Etanercept vs placebo)	1	174	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.86, 1.06]
2.11.2 Partial remission (infliximab vs rituximab)	1	17	Risk Ratio (M‐H, Random, 95% CI)	0.89 [0.07, 12.00]